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STUDY QUESTIONS: The objective of this study is to evaluate the effectiveness and cost-effectiveness of surgical treatment of women
suffering from pain due to an ovarian endometrioma when compared to treatment with medication (analgesia and/or hormones). The primary
outcome is defined as successful pain reduction (−30% reduction of pain) measured by the numeric rating scale (NRS) after 6 months. Secondary
outcomes include successful pain reduction after 12 and 18 months, quality of life, affective symptoms, cost-effectiveness, recurrence rate, need
of adjuvant medication after surgery, ovarian reserve, adjuvant surgery and budget impact.
WHAT IS KNOWN ALREADY: Evidence suggests that both medication and surgical treatment of an ovarian endometrioma are effective
in reducing pain and improving quality of life. However, there are no randomised studies that compare surgery to treatment with medication.
STUDY DESIGN, SIZE, DURATION: This study will be performed in a research network of university and teaching hospitals in the
Netherlands. A multicentre randomised controlled trial and parallel prospective cohort study in patients with an ovarian endometrioma, with
the exclusion of patients with deep endometriosis, will be conducted. After obtaining informed consent, eligible patients will be randomly
allocated to either treatment arm (medication or surgery) by using web-based block randomisation stratified per centre. A successful pain
reduction is set at a 30% decrease on the NRS at 6 months after randomisation. Based on a power of 80% and an alpha of 5% and using a
continuity correction, a sample size of 69 patients in each treatment arm is needed. Accounting for a drop-out rate of 25% (i.e. loss to follow
up), we need to include 92 patients in each treatment arm, i.e. 184 in total. Simultaneously, a cohort study will be performed for eligible patients
who are not willing to be randomised because of a distinct preference for one of the two treatment arms. We intend to include 100 women
in each treatment arm to enable standardization by inverse probability weighting, which means 200 patients in total. The expected inclusion
period is 24 months with a follow-up of 18 months.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Premenopausal women (age ≥ 18 years) with pain (dysmenorrhoea, pelvic pain
or dyspareunia) and an ovarian endometrioma (cyst diameter ≥ 3 cm) who visit the outpatient clinic will make up the study population. Patients
with signs of deep endometriosis will be excluded. The primary outcome is successful pain reduction, which is defined as a 30% decrease of pain
on the NRS at 6 months after randomisation. Secondary outcomes include successful pain reduction after 12 and 18 months, quality of life and
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of adjuvant medication after surgery, ovarian reserve and recurrence rate of endometriomas. Measurements will be performed at baseline,
6 weeks and 6, 12 and 18 months after randomisation.
STUDY FUNDING/COMPETING INTEREST(S): This study is funded by ZonMw, a Dutch organization for Health Research and
Development, project number 80-85200-98-91041. The Department of Reproductive Medicine of the Amsterdam UMC location VUmc
has received several research and educational grants from Guerbet, Merck KGaA and Ferring not related to the submitted work. B.W.J. Mol is
supported by a NHMRC Practitioner Fellowship (GNT1082548) and reports consultancy for ObsEva, Merck KGaA and Guerbet. V. Mijatovic
reports grants from Guerbet, grants from Merck and grants from Ferring outside the submitted work. All authors declare that they have no
competing interests concerning this publication.
TRIAL REGISTRATION NUMBER: Dutch Trial Register (NTR 7447, http://www.trialregister.nl).
TRIAL REGISTRATION DATE: 2 January 2019
DATE OF FIRST PATIENT’S ENROLMENT: First inclusion in randomised controlled trial October 4, 2019. First inclusion in cohort May
22, 2019.
Key words: endometrioma / pain / quality of life / cost-effectiveness / affective symptoms / recurrence / ovarian reserve / surgery /
medication / randomised controlled trial
WHAT DOES THIS MEAN FOR PATIENTS?
Endometriosis is a painful condition in which tissue similar to the lining inside the womb (uterus) is found outside the uterus. This is described
as an endometrioma when this tissue has caused an ovarian cyst. When these ovarian cysts cause pain, two therapeutic strategies are currently
available. They include treatment with medication (pain relief and/or hormones) and surgery. Evidence suggests that both treatments are
effective in reducing pain symptoms and increasing quality of life. However, it is not clear which treatment is the most effective. In this study,
women with an endometrioma receiving medication will be compared to women treated by surgery. We will investigate the effect on pain and
quality of life. We also want to investigate whether surgery could save costs both for the healthcare system and society in general (e.g. if women
cannot work because of illness).
Introduction
Endometriosis is defined as the presence of endometrium-like tissue
outside the uterine cavity causing a chronic inflammatory reaction.
The prevalence varies between 2 and 10% among the general female
population of reproductive age (Eskenazi and Warner, 1997), but rises
up to 30–40% in women suffering from cyclical pain and/or infertility
(Meuleman et al., 2009). Endometriosis is associated with symptoms
of pelvic pain, dysmenorrhea, dyspareunia and infertility, causing a
significant reduction in quality of life (QoL), which is largely mediated
by psychological distress (De Graaff et al., 2013). The population of
women suffering from endometriosis shows 0.81 quality-adjusted life
years (QALY) (Simoens et al., 2012), resulting in a high socio-economic
burden. The EndoCost study calculated these annual costs at e2.6
billion in the Netherlands (Simoens et al., 2012). This burden is largely
caused by the indirect costs of productivity loss (loss of 10.8 working
hours per week, e6298 per woman per year) (Nnoaham et al., 2011;
Simoens et al., 2012). One of the most common manifestations of
endometriosis is the formation of an ovarian endometrioma, affect-
ing 17–44% of women with endometriosis (Eskenazi et al., 1997).
Endometriomas are ovarian inclusion cysts lined with endometrial tis-
sue in which the internal fluid is thought to result from the accumulation
of menstrual blood deriving from the shedding of endometrial lining
inside the cyst. Optimal, evidence-based and cost-effective treatment
of an endometrioma is necessary in order to decrease pain, improve
QoL and affective symptoms, and lower the socio-economic burden.
Two therapeutic strategies, including treatment with medication





























































ment of ovarian endometriomas. None of these treatment options
offer a cure, but aim to reduce pain and increase QoL. Evidence
from observational studies suggests that both therapeutic strategies are
effective in reducing pain symptoms.
When performing surgery, cystectomy is superior to drainage and
coagulation in women with an ovarian endometrioma (≥3 cm) with
regard to the recurrence of endometriosis-associated pain and the
recurrence of endometriomas. Two randomised controlled trials
(RCTs) comparing cystectomy to drainage and coagulation by bipolar
diathermy demonstrated 24-month cumulative recurrence rates of
dysmenorrhea, deep dyspareunia and non-menstrual pelvic pain of 10–
20%. These studies indicated that laparoscopic cystectomy achieved
relief of pain symptoms (visual analogue scale (VAS) score ≤ 5) in 80–
94.7% in the first year after treatment (Beretta et al., 1998; Alborzi
et al., 2004).
The use of low-dose cyclic oral contraceptives is effective in reducing
pain symptoms in patients with endometriosis. At the end of a 6-month
treatment period with low-dose combined oral contraceptives, non-
menstrual pain (40%), dyspareunia (75%) and dysmenorrhoea (82.6%)
were reduced to mild or zero in comparison with baseline. These
results were compared to the GnRH agonist goserelin. For dyspare-
unia, goserelin was superior to oral contraceptives, while for non-
menstrual pain there was no difference (Vercellini et al., 1993; Brown et
al., 2010). Anti-progestogens are efficient in reducing dysmenorrhoea
(resulting in none or mild painful dysmenorrhoea after 6 months of
follow-up) in 67.3% of cases and depot progestin in 89.5% (Brown
et al., 2012).
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Table I Secondary outcomes in a comparison of surgery or medication for women with an endometrioma.
Successful pain reduction after 12 and 18 months NRS at 12 and 18 months.
.........................................................................................................................................................................................
Quality of life EuroQoL-5D-5L and EHP30 questionnaires.
Affective symptoms GAD-7 and PHQ-9 questionnaires.
Costs effectiveness iMCQ and iPCQ.
Recurrence rate Recurrence of either pain symptoms (measured on the NRS as described above) and the
endometrioma itself (measured with ultrasound).
Need of adjuvant medication after surgery Patients’ medical file.
Ovarian reserve Measured by blood test (serum AMH levels∗) and ultrasound (AFC).
Adjuvant surgery Rate of adjuvant surgery after treatment with medication for endometrioma.
Budget impact Total costs from the group treated with medication and the group treated by surgery.
EuroQol-5D-5 L = European quality of life – 5 Dimensions – 5 Levels; EHP-30 = Endometriosis Health Profile-30; QALY = quality-adjusted life year; GAD-7 = Generalized Anxiety
Disorder-7; PHQ-9 = Patient Health Questionnaire-9; iMCQ = Medical Consumption Questionnaire; iPCQ = Productivity Cost Questionnaire; NRS = numeric rating scale; AMH = anti-
Müllerian hormone; AFC = antral follicle count.
∗AMH will not be measured in the prospective cohort study. See Fig. 1 (flowchart with study procedures) for details about the timing of measuring the parameters.
However, there are no randomised studies that compare surgery to
medication in the treatment of an ovarian endometrioma. This forces
women with endometriosis and their physicians to take decisions in
uncertainty about the benefits, risks and cost-effectiveness of surgery
in direct comparison to treatment with medication.
As a result of this uncertainty about the relative effectiveness and
cost-effectiveness of the two treatments, usual care is characterised
by the co-existence of two therapeutic strategies. Treatment with
medication (analgesics and/or hormones) may alleviate symptoms,
but the effect is temporary and considered less effective since the
endometriosis cyst is not removed. This strategy requires chronic use
of analgesics and hormones, plus frequent monitoring of the cyst and
the associated symptoms. Furthermore, if endometriomas are not
removed women may experience insufficient pain relief, exacerbations
of pain symptoms requiring hospital visits and admission and/or cyst-
related complications such as rupture and torsion (4%) (Bottomley and
Bourne 2009). When this strategy is applied, surgery is frequently still
necessary as a result of these disadvantages.
As surgical removal of the cyst implies that the source of pain
is eliminated, it is considered to be the most effective treatment
in reducing pain symptoms. Surgery also appears to be more cost-
effective than conservative treatment, as patients who have under-
gone surgery are less likely to require additional medication for pain
relief or to return to the hospital for scheduled or emergency vis-
its related to complications associated with ovarian endometriomas.
Traditionally, there was a general experts’ consensus that removal of
an endometrioma is the treatment of choice in patients with cysts
larger than 3 cm, but this consensus has been challenged by evidence
questioning the benefit and harm of surgery. One of the risks of surgery
is recurrence of the cyst, causing relapse of symptoms, questioning
both the benefit and cost-effectiveness of surgery (Alborzi et al.,
2004; Dan and Lemin 2013). Furthermore, several studies showed
that healthy ovarian tissue is accidentally removed during cystectomy
(Dunselman et al., 2014), potentially causing loss of ovarian reserve
and lowering the chances for accomplishing a successful pregnancy
in the future. Alternative treatments to cystectomy include (partial)





















































































et al., 2010; Carmona et al., 2011) and argon plasma energy (Roman
et al., 2015). The best treatment of endometriomas is unknown, and
this topic has been prioritised as a knowledge gap by ESHRE Guideline
Development Group (Dunselman et al., 2014) and the Dutch Society
of Obstetrics and Gynaecology (NVOG 2016). In this study, we will
investigate surgery in comparison to treatment with medication in
order to eliminate the less (cost-)efficient strategy.
Outcomes
Primary outcome
The primary outcome is effectiveness of surgical treatment compared
to treatment with medication of an ovarian endometrioma, defined as
successful pain reduction (−30% reduction of pain) measured by the
numeric rating scale (NRS) after 6 months.
Patients may experience pelvic pain, dysmenorrhea and/or deep
dyspareunia caused by an ovarian endometrioma. During follow-up,
the patient will be asked to score the average pain level for pelvic pain
during the last week and, if applicable, the average pain for dysmen-
orrhea and deep dyspareunia during the last month. Physicians will be
instructed to ask for pain scores using an 11-point numerical rating scale
(0–10). These scales should be anchored by 0 = ‘no pain’ and 10 = ‘the
worst pain you can imagine’ (Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials (IMMPACT) and American Society
for Reproductive Medicine (ASRM) recommendation).
Secondary outcomes
The secondary outcomes are listed in Table I. Measurements will be
performed at baseline (t0), 6 weeks (t1), 6 months (t2), 12 months
(t3) and 18 months (t4) after randomisation.
Baseline characteristics
The baseline characteristic collected at start of the study will include
demographic data and medical history. Pre-treatment characteristics
include hormonal treatment and previous surgery, ultrasound data and
mean pain scores for dysmenorrhea, dyspareunia and chronic pelvic
pain.
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Materials and Methods
This protocol describes a multicentre RCT with cost-effectiveness
analysis and preference cohort study. The study will be performed




In order to be eligible to participate in this study, a subject must meet
all of the following criteria:
• Premenopausal woman aged ≥18 years;
• Patients who report at least one of the endometriosis related pain
symptoms: dysmenorrhoea, pelvic pain or dyspareunia;
• Ovarian endometrioma with a cyst diameter ≥ 3 cm (measured by
transvaginal ultrasound or MRI).
Exclusion criteria
A potential subject who meets any of the following criteria will be
excluded from participation in this study:
• Women with signs of deep endometriosis∗ (by physical examination
and transvaginal ultrasound or MRI);
• Not able or willing to provide written informed consent;
• Not able to read, write and understand Dutch or English.
∗Deep endometriosis extends beneath the peritoneum and may affect the
uterosacral ligaments, pelvic sidewalls, rectovaginal septum, vagina, bowel,
bladder or ureter (Dunselman et al., 2014).
The study schedule is presented in the flowchart (Fig. 1). Patients
meeting the inclusion and exclusion criteria will be verbally informed
about the study by their physician who will provide them with written
information. Each subject will be informed that participation in the
study is voluntary and that withdrawal of consent will not affect
her right to the most appropriate treatment or affect the patient–
doctor relationship. If a patient agrees to participate in the study
after the consideration time of 1 week, written informed consent
will be obtained after which randomisation will be performed.
Women will be randomly allocated in a 1:1 ratio to either surgery
or treatment with medication, with use of dynamic block designed
randomisation with blocks of 2, 4 or 6. Stratification by centre will be
performed.
Women who decline randomisation due to a specific treatment
preference for one of the treatments will be asked to participate in
a prospective cohort according to the study protocol. The primary
outcome of the randomised trial (successful pain reduction (−30%
reduction of pain) measured by the NRS after 6 months) will be
presented as the headline result. Addition of the prospective cohort
enables us to:
• Observe the expected outcome outside the context of the trial and
to compare this to the outcome of the RCT, which will provide
knowledge on the generalizability of the findings;
• Increase the precision of the estimate of the findings from the
RCT by making groups comparable (standardization by inverse





























































































































Figure 1 Flowchart of procedures in a study of surgery versus
medication for women with an endometrioma. AFC = antral follicle
count; NRS = numeric rating scale; RCT = randomised controlled trial;
AMH = anti-Müllerian hormone; QoL = quality of life; FU = follow-up.
Surgical treatment of an endometrioma will be compared to treat-
ment with medication. Both treatment strategies are currently used
for treatment of women with pain symptoms related to an ovarian
endometrioma and are considered as usual care.
Surgical treatment of ovarian endometriomas will be performed by
gynaecologists according to the technical description and recommen-
dations by the Working Group of ESHRE, the European Society for
Gynaecological Endoscopy and the World Endometriosis Society. The
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ESHRE guideline concludes that laparoscopic cystectomy is superior
to drainage and coagulation in women with an ovarian endometrioma
(≥3 cm) with regard to the recurrence of endometriosis-associated
pain and the recurrence of the endometrioma. Cystectomy is probably
more effective than CO2 laser vaporization in women with ovarian
endometriomas (≥3 cm) with regard to recurrence of endometriomas
Carmona et al., 2011). An alternative surgical treatment includes abla-
tion with Argon plasma energy (Roman et al., 2015; Lockyer et al.,
2019). Adherence to the standard operating procedure will be assessed
by checking operation reports. Treatment with medication includes
analgesics and/or hormonal therapy for 6 months followed by revision
of pain relief. Therapy with analgesics is based on the World Health
Organisation (WHO) analgesic ladder (WHO, 1986). Options for
hormonal therapy are oral contraceptive pills, progestogens, anti-
progestogens or GnRH agonists. Women who experience sufficient
pain relief will continue treatment with medication. If women experi-
ence insufficient pain relief at 6 months of follow-up, surgical treatment
will be offered.
During the screening, a transvaginal ultrasound will be performed to
determine the diameter of the ovarian endometrioma, the antral folli-
cle count (AFC) and the presence of signs related to deep endometrio-
sis. After randomisation, baseline characteristics and medical history
will be listed in the case report file and one blood sample will be
obtained in order to measure serum anti-Müllerian hormone (AMH).
At baseline, and at 6 weeks, 6 months, 12 months and 18 months of
follow-up, participants will be asked to complete validated question-
naires on QoL and affective symptoms. Cost questionnaires will be
assigned at 6, 12 and 18 months of follow-up. Transvaginal ultrasounds
and blood samples will be repeated in order to determine recurrences
of ovarian endometriomas and the ovarian reserve (by AFC and serum
AMH) at 6, 12 and 18 months of follow-up.
Missing values are minimised through active trial monitoring within
the NVOG Consortium 2.0.
Data are collected prospectively as part of routine care. A secure
online tool will be used to collect results from the questionnaires
(Castor EDC®).
Most of the study visits will be combined with regular care visits and
activities in order to reduce the burden of participation in this study.
In regular care, patients treated with medication visit the outpatient
clinic four times a year for routine follow-up. Therefore, there are
no additional study visits for patients treated with medication. How-
ever, patients treated by surgery only visit the outpatient clinic after
6 weeks for post-operative follow-up. Therefore, participating in the
surgical arm of the study requires three additional visits (at 6, 12 and
18 months).
Sample size
Olsena et al. (2018) included 66 studies to define the minimum clinically
important differences (MCID) in chronic pain. Median absolute MCID
was estimated between 23 and 34% among studies using the mean
change approach (Olsena et al. 2018). According to the IMMPACT rec-
ommendations, reductions in chronic pain intensity of 30% appear to
reflect at least moderate clinically important changes and will therefore
be considered as successfully treated and this was used for sample
size calculation. We assume that surgery will result in successful pain





























































































































in successful pain reduction in 70% of women (Vercellini et al., 1993;
Beretta et al., 1998; Alborzi et al., 2004; Brown et al., 2010; Brown
et al., 2012). Based on a power of 80% and an alpha of 5% and using a
continuity correction, a sample size of 69 patients in each treatment
arm is needed. Accounting for a dropout rate of 25% (i.e. loss to
follow-up), we need to include 92 patients in each arm, i.e. 184 in total.
As for the cohort study, we expect women to choose both treatment
options in a similar ratio (1:1). Simultaneously, a cohort study will be
performed for eligible patients who are not willing to be randomised
because they have a distinct preference for one of the two treatment
arms. We intend to include 100 women in each treatment arm to
enable standardization by inverse probability weighting, which means
200 patients in total. The expected inclusion period is 24 months while
the follow-up period is 18 months.
Statistical Analysis
Primary and secondary study parameter(s)
Data analysis will be by both intention to treat and per protocol
analysis. The primary outcome (successful pain relief ) as well as the
secondary outcome (recurrence rate) will be expressed as relative risks
with 95% CI and as odds ratio (OR) with 95% CI, controlled for centre
by using a logistic regression analysis. Differences between groups for
change over time will be analysed with Kaplan–Meier analysis and a log
rank test, and we will control for centre in a Cox regression analysis. To
assess differences in secondary continuous outcomes, such as pain on
a continuous scale and QoL and affective symptom measures, we will
use linear mixed models. The per protocol analysis will be performed
for participants that did not cross over to the other treatment arm and
had a follow-up time of at least 12 months. In case of missing outcome
data at 12 and 18 months, a sensitivity analysis will be performed using
a last case carried forward. With regard to the remaining secondary
outcomes, between-group difference of the proportions and means
will be expressed as two-sided 95% CI at 6, 12 and 18 months. Multiple
imputation will be used in case of missing co-variables.
Cost-effectiveness
The aim of the economic evaluation is to relate the incremental costs
of laparoscopic surgical treatment (intervention) in comparison to
treatment with medication (analgesics and/or hormones, control) to
the incremental health effects. Both a cost-effectiveness analysis and a
cost-utility analysis will be performed from a societal and healthcare
perspective according to Dutch guidelines with a time horizon of
18 months (Zorginstituut Nederland, 2016).
Measurement and valuation of costs
Costs will be measured from a societal perspective using web-based
questionnaires based on the Medical Consumption Questionnaire
(iMCQ) and Productivity Cost Questionnaire (iPCQ) after 6, 12 and
18 months of follow-up. Cost categories included are as follows:
• Healthcare costs (primary and secondary care, complementary care
and home care);
• Lost productivity costs (absenteeism from paid and unpaid work,
and presenteeism);
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• Patient costs (informal care and other care services paid for by
patients themselves).
Valuation will be carried out according to Dutch costing guidelines
(Hakkaart-Van Roijen et al., 2016). For the valuation of healthcare
utilization, lost productivity and informal care, the Dutch standard
costs will be used. Medication use will be valued using prices of the
Royal Dutch Society for Pharmacy. Patient and family costs other than
informal care will be valued using self-reported prices. For the valuation
of absenteeism from paid work, the friction cost approach will be used.
Patient outcome analysis in the economic evaluation
The following effect measures will be included in the economic
evaluation:
• Successful pain reduction (defined as 30% reduction in pain);
• Recurrence rate defined as either recurrence of pain or the recur-
rence of ovarian endometriomas (ultrasound);
• QALY (EuroQoL-5 Dimensions—5 Levels (EQ-5D-5L) with Dutch
reference values) (Versteegh et al., 2016).
Missing cost and effect data will be imputed using multiple imputation
according to the MICE algorithm developed by van Buuren (van Buuren
et al., 1999). Rubin’s rules will be used to pool the results from the
different multiple imputed datasets. Bivariate regression analyses will
be used to estimate cost and effect differences between intervention
and control while adjusting for confounders if necessary. Incremental
cost-effectiveness ratios (ICERs) will be calculated by dividing the
difference in the mean total costs between the treatment groups by
the difference in mean effect between the treatment groups. Bias-
corrected and accelerated bootstrapping with 5000 replications will
be used to estimate 95% CI around the cost differences and sta-
tistical uncertainty surrounding the ICERs. Uncertainty surrounding
ICERs will be graphically presented on cost-effectiveness planes. Cost-
effectiveness acceptability curves will also be estimated showing the
probability that the intervention is cost-effective in comparison with
control for a range of different ceiling ratios, thereby showing decision
uncertainty (Fenwick et al., 2004).
Budget impact analysis
A budget impact analysis (BIA) will be conducted from the perspec-
tive of healthcare decision makers according to the Dutch guidelines
(Hakkaart et al., 2016) and the recommendations from Sullivan et al.
(2014). In the BIA, data from the effectiveness and cost-effectiveness
analyses regarding the differences in costs and health outcomes will be
combined with national prevalence and incidence data to extrapolate
the findings to a time horizon of 5 years. The BIA will be conducted
from the government perspective (Budget Kader Zorg). Actual Dutch
Healthcare Authority (NZA) tariffs will be used to calculate costs.
The budget analyses will differentiate between incidental and struc-
tural cost (savings) and take into account budgetary consequences
of changes within these cost components. Sensitivity analyses will be
performed for subgroups of patients, providing budget information for
relevant subgroups to decision makers. In addition, sensitivity analyses
will address the impact of variations of the main assumptions and
input parameters for the BIA. The potential recurrence of symptoms
and decreased ovarian reserve is one of the aspects that will be






























































































































The processing of personal data complies with the EU General Data
Protection Regulation (GDPR) and the Dutch Act on Implementation
of the General Data Protection Regulation (in Dutch: Uitvoeringswet
AVG, UAVG). Data will be collected in a web-based registry (Castor
EDC®). The computer will randomly assign a unique numeric code
for every subject that bears no relation to initials or date of birth.
Data processing will be done with coded data, with the key (code to
personal information linkage) only available to the local investigator and
the research nurse working in the local centre. Persons who have access
to the data include investigators, research staff, monitoring and quality
assurance personnel. The personal data will be stored for a maximum
of 15 years.
Monitoring
Monitoring will be performed in compliance with Good Clinical Prac-
tice and Dutch rules and regulations in order to achieve high quality
research and secure patient safety. Qualified and independent monitors
from the NVOG Consortium 2.0 will have access to the data and
source documents of the trial. Based on the site-specific monitoring
plan of the NVOG Consortium 2.0, monitoring visits in each participat-
ing Dutch site will be performed every year. The independent monitor
will have access to the data and source documents of the trial to review
the quality of the participating sites.
Ethical approval
This study is approved by the National Central Committee on Research
involving Human Subjects (CCMO—NL67922.015.18) and by the
institutional review board ethics committee of the Máxima Medical
Centre (Ref. No. W18.149), covering all participating centres under
Dutch law and by the boards of all participating hospitals. The trial is
registered in the Dutch Trial Register (NTR No. 7689).
Discussion
The best treatment for ovarian endometrioma-related pain symptoms
is unknown and this has been prioritised as a knowledge gap by
NVOG and the ESHRE Guideline Development Group (NVOG 2016;
Dunselman et al., 2014). A review from Johnstone and Link et al. (2015)
included articles describing the effectiveness of hormonal therapy and
surgery in patients with an ovarian endometrioma. The reviewed RCTs
did not support a single treatment modality in all cases. The literature
reveals many unanswered questions and concludes that RCTs compar-
ing primary treatment with medication to surgery for endometrioma-
associated pain are needed. The current lack of evidence obstructs
shared decision-making, since women cannot be informed in a balanced
way about the risks and benefits of their therapeutic choices. The
SOMA-trial is the first well-designed large RCT that will compare
surgery to medication in women with an ovarian endometrioma in the
absence of deep endometriosis. To our knowledge, there are currently
no other trials that evaluate both treatment regimens in this patient
population.
The SOMA-trial is a care evaluation. Both treatment with medication
and surgery are part of the standard care offered to patients with
ovarian endometriomas. Therefore, no additional risks are expected
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for SOMA trial participants. Every medical treatment option will be
considered as ‘control’ and will be compared to surgery as one group.
Owing to the different application forms of medication and the physical
component of surgical treatment, blinding is not feasible in this trial,
which could result in detection and performance bias. The risk of bias is
reduced by random allocation of patients to the medication or surgery
group, respectively. Block randomisation, stratified for each participat-
ing centre, will be web-based which will reduce the chance of allocation
bias. The sample size calculation was performed by a methodologist
from the Consortium 2.0 (MvW). The same methodologist will also
perform the data analysis by intention-to-treat principle, which will
provide unbiased comparisons among the treatment groups. Because
the SOMA-trial is a care evaluation, the intention-to-treat analysis will
provide information on the outcomes of treatment strategy (medica-
tion versus surgery) rather than on a specific treatment with medication
or surgical treatment option.
In order to answer the research questions regarding pain reduction,
QoL, affective symptoms and cost-effectiveness, validated question-
naires will be used. These questionnaires have been validated for the
English and Dutch language. The Endometriosis Health Profile-30 is a
reliable and valid instrument that is particularly appropriate for use in
clinical trials in order to assess the effectiveness of medical or surgical
therapies for endometriosis on the health-related QoL (Jones et al.,
2004; van de Burgt et al., 2011). The Generalized Anxiety Disorder-7
is a valid and efficient tool for screening for general anxiety disorder
and assessing its severity in clinical practice and research (Spitzer et al.,
2006; Donker et al., 2011). In addition to making criteria-based diag-
noses of depressive disorders, the Patient Health Questionnaire-9
(PHQ-9) is also a reliable and valid measure of depression severity.
These characteristics and its brevity make the PHQ-9 a useful clinical
and research tool (Kroenke et al., 2001; Zuithoff et al., 2010). Costs
will be measured from a societal perspective using internet question-
naires based on the iMCQ (Bouwmans, 2013a) and iPCQ (Bouwmans,
2013b). The EuroQol-5D will be used to determine the QALYs, as
QALYs are widely used as an outcome for the economic evaluation
of health interventions (Versteegh et al., 2016).
The current care for women with endometriosis is described
in the ESHRE guideline (Dunselman et al., 2014) and is fully
adopted by the NVOG. This guideline recommends clinicians to
thoroughly counsel women with symptoms presumed to be due
to endometriosis and to empirically treat them with adequate
analgesia combined with hormonal treatment or surgery, taking into
account the patient’s preferences and the side effects, efficacy, costs
and availability.
In this guideline, clinicians are recommended to prescribe hor-
monal treatment (hormonal contraceptives, progestagens, anti-
progestogens or GnRH agonists as one of the options), as it reduces
endometriosis-associated pain (Vercellini et al., 1993; Brown et al.,
2010; Brown et al., 2012). The effectiveness of analgesics such as non-
steroidal anti-inflammatory drugs (NSAIDs) in treating endometriosis-
associated dysmenorrhea is not well established owing to a lack
of studies. However, there is good evidence that NSAIDs have a
favourable effect on primary dysmenorrhea (Marjoribanks et al.,
2010). Surgery is also effective with regard to pain relief (Beretta
et al., 1998; Alborzi et al., 2004). In addition, several arguments
may be presented in favour of surgical removal of endometriomas.































































































































rupture and torsion, causing potential loss of the ovary. Secondly,
endometriomas are associated with a slightly increased risk of
malignancy (OR = 1.34; 95% CI 1.03–1.75 (Borgfeldt and Andolf,
2004)), which may favour removal and histological examination even
though prophylactic removal is not recommended (Dunselman et al.,
2014). Finally, removal of endometriomas may increase spontaneous
pregnancy rates (Nezhat et al., 1989; Vercellini et al., 2006). However,
we have to keep in mind that these studies were performed in an
observational setting lacking a control group. Therefore, this favourable
outcome could be overestimating the benefit of surgery. Furthermore,
superficial peritoneal endometriosis may be more easily diagnosed
in the surgical arm and we expect surgeons, given their surgical
instinct and current best practice, to treat these lesions as well (e.g.
excision or ablation). Although this fulfils the intention-to-treat basis,
this might influence pain reduction in this group when compared
to the control group. Therefore, the presence and (if applicable)
subsequent treatment of superficial peritoneal endometriosis will be
registered in the SOMA-trial. A disadvantage of surgical treatment
could be a decrease in ovarian reserve following surgical excision
through removal of cyst lining as well as parts of the underlying
ovarian cortex. This is substantiated by the following observations:
the rate of spontaneous ovulation is lower in operated ovaries,
and serum levels of AMH decrease after surgical excision of an
endometrioma (Kovačević et al., 2018). In women selected for IVF,
responsiveness to ovarian hyperstimulation, the number of developing
follicles and the number of oocytes retrieved are reduced in the
ovary where an endometrioma has been surgically treated (Somigliana
et al., 2003; Ragni et al., 2005; Gupta et al., 2006; Duru et al., 2007).
Last, but not least, after removal of bilateral endometriomas, clinical
pregnancy and delivery rates after IVF are significantly impaired
(Somigliana et al., 2008).
For the management of pain symptoms, the ESHRE guideline did
focus on improving pain prior to using ART, but had no recommen-
dation for treatment of pain symptoms alone.
The SOMA-trial is the first RCT that will compare surgery to medi-
cation in women with an endometrioma. This study will add evidence-
based information and will improve the quality of future guideline
recommendations. Furthermore, it provides the establishment of a
unique cohort for long-term follow-up in order to gain prospective
knowledge about pregnancy and recurrence rates and malignant poten-
tial of endometriomas.
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